Trial Profile
ATHENAS - Retrospective Analysis of Compliance to Treatment of Chronic Hepatitis C With Pegylated Interferon Alpha 2b Associated to Ribavirin Until Week 12 and Correlation With Virological Response in Brazil Health Centers.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2b/ribavirin (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ATHENAS
- Sponsors Merck Sharp & Dohme Corp.
- 14 Oct 2011 Actual patient number added 902 according to ClinicalTrials.gov.
- 10 Feb 2011 Actual End Date (1 Oct 2010) added as reported by ClinicalTrials.gov.
- 10 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.